Roche kidney disease drug succeeds in Phase 3 trial for IgA nephropathy

Roche Holding and Ionis Pharmaceuticals announced on September 23, 2026, that their experimental drug sefaxersen met its primary endpoint in a Phase 3 trial for IgA nephropathy. Sefaxersen achieved statistically significant reductions in proteinuria, a key marker of kidney damage. Administered as a once-monthly subcutaneous injection, the drug targets complement factor B to prevent kidney inflammation. If approved, sefaxersen will enter a highly competitive market alongside Novartis' Fabhalta, which is priced at $400,000 to $500,000 annually.

Sefaxersen Phase 3 Trial Results

• ▪Interim results from a Phase 3 clinical trial for IgA nephropathy showed that sefaxersen led to statistically significant and clinically meaningful reductions in proteinuria, a key indicator of kidney damage
• ▪Roche Holding and Ionis Pharmaceuticals announced on September 23, 2026, that their experimental drug sefaxersen met its primary endpoint in a Phase 3 clinical trial for IgA nephropathy
• ▪Roche Holding and Ionis Pharmaceuticals plan to share the interim Phase 3 data for sefaxersen with health authorities to seek regulatory approval and present the findings at an upcoming medical meeting

About IgA Nephropathy

• ▪IgA nephropathy can lead to progressive kidney damage, and effective treatments are designed to help patients preserve long-term kidney function and avert expensive kidney dialysis or transplants
• ▪IgA nephropathy, also known as Berger's disease, is an autoimmune disorder occurring when rogue antibodies enter the kidneys and form clumps that cause inflammation and impede organ function

Dosing and Administration

• ▪William Blair analyst Myles Minter stated that sefaxersen's monthly dosing via an autoinjector is relatively competitive, with only Vertex Pharmaceuticals' experimental drug having a similar profile
• ▪Sefaxersen is administered as a once-monthly subcutaneous self-injection, which Roche Holding and Ionis Pharmaceuticals pitch as a more convenient alternative to Novartis' twice-daily oral pill, Fabhalta

Competitive Landscape

• ▪If sefaxersen is approved, it would compete in a crowded market against Novartis' Fabhalta, which is priced at approximately $400,000 to $500,000 a year
• ▪The Food and Drug Administration has granted accelerated clearances for IgA nephropathy drugs from Otsuka Pharmaceutical and Vera Therapeutics, with Calliditas, Travere, and potentially Vertex Pharmaceuticals also in the IgA nephropathy market

Roche Holding financial outlook

• ▪Roche Holding's base business is experiencing slow growth as the Swiss pharmaceutical giant absorbs patent expirations for key products
• ▪RBC Capital Markets analyst Trung Huynh identified sefaxersen, breast cancer drug giredestrant, and multiple sclerosis treatment fenebrutinib as underappreciated assets that could boost Roche Holding's earnings